Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity

References

• Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myeloma Autogreffe. J Clin Oncol 2005; 23: 9227–9233.
   PubMed Web of Science ®Google Scholar
• Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904–1912.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645–2654.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. The Oncologist 2010; 15: 6–25.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hemat 2011; 87: 79–88.
   Web of Science ®Google Scholar
• Bargetzi MJ, Passweg J, Baertschi E, et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003; 31: 99–103.
   PubMed Web of Science ®Google Scholar
• Heizmann M, O’Meara AC, Moosmann PR, et al. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. Bone Marrow Transplant 2009; 44: 75–79.
   PubMed Web of Science ®Google Scholar
• Samaras P, Pfrommer S, Seifert B, et al. Efficacy of vinorelbine plus G-CSF for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biol Blood Marrow Transplant 2015; 21: 74–80.
   PubMed Web of Science ®Google Scholar
• Schmid A, Friess D, Mansouri Taleghani B, et al. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma 2015; 56: 608–614.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112: 1–11.
   PubMed Web of Science ®Google Scholar
• Carlson K, Ocean AJ. Peripheral neuropathy associatd with microtubule-targeting agents: occurence and management approach. Clinical Breast Cancer 2011; 11:73–81.
   PubMed Web of Science ®Google Scholar
• Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010; 11: 1086–1095.
   PubMed Web of Science ®Google Scholar
• Keller S, Seipel K, Novak U, et al. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Leuk Res 2015; 39: 786–792.
   PubMed Web of Science ®Google Scholar
• Koeppen S. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy. Oncol Res Treat 2014; 37: 506–513.
   PubMed Web of Science ®Google Scholar
• Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010; 95: 311–319.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113–3120.
   PubMed Web of Science ®Google Scholar
• Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008; 6: 455–467.
   PubMedGoogle Scholar
• Suyani E, Sucak GT, Aki SZ, et al. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011;90: 658–691.
   Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279–3288.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010; 51:1178–1187.
   PubMed Web of Science ®Google Scholar
• Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN Task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 2009; 7: 1–26.
   PubMed Web of Science ®Google Scholar
• Capasso A. Vinorelbine in cancer therapy. Curr Drug Targets 2012; 13: 1065–1071.
   PubMed Web of Science ®Google Scholar
• Galano G, Caputo M, Tecce MF, Capasso A. Efficacy and tolerability of vinorelbine in the cancer therapy. Curr Drug Safety 2011; 6: 185–193.
   PubMedGoogle Scholar
• Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastin, vincristine, and vinorelbine. Biochemistry 1996; 31: 5374–5380.
   Google Scholar
• Tacchetti P, Terragna C, Galli M, et al. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hemat 2014; 89: 1085–1091.
   PubMed Web of Science ®Google Scholar
• Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nature Rev Neurosci 2006; 7: 797–809.
   PubMed Web of Science ®Google Scholar